Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
#MarketsWithMC | Biocon shares hit 52-week high as subsidiary receives FDA nod for diabetes drug 📊📈 #Biocon #Shares #Markets #FDA More Details ⬇️🔗 https://t.co/ypSA2wgI6B
Biocon Biologics gets USFDA nod for diabetes medication https://t.co/ESBJVkEpCT
#Biocon shares near 52-week high after #USFDA approves key diabetes treatment drug @ekta_batra @hormaz_fatakia https://t.co/1vmn0x4vEL
Biocon Biologics has received approval from the U.S. Food and Drug Administration (FDA) for Kirsty™, the first interchangeable rapid-acting insulin aspart biosimilar available in a prefilled pen. Kirsty™ is an interchangeable biosimilar of NovoLog®, expanding Biocon's diabetes treatment portfolio in the United States. Following the FDA nod, Biocon's shares rose over 2%, reaching a 52-week high. This approval marks a key development for Biocon Biologics in the diabetes medication market.
